<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="http://www.allontherapeutics.com/wp-content/plugins/google-sitemap-generator/sitemap.xsl"?><!-- generator="wordpress/3.1" -->
<!-- sitemap-generator-url="http://www.arnebrachhold.de" sitemap-generator-version="3.2.5" -->
<!-- generated-on="February 14, 2012 9:39 pm" -->
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">	<url>
		<loc>http://www.allontherapeutics.com/</loc>
		<lastmod>2011-08-03T19:16:05+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>1.0</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/corporate/news/events-and-webcasts/</loc>
		<lastmod>2012-02-14T21:39:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2012/02/allons-data-safety-monitoring-board-recommends-continuation-of-pivotal-clinical-trial/</loc>
		<lastmod>2012-02-11T01:54:09+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/product-development/davunetide/</loc>
		<lastmod>2012-02-06T17:56:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/investors/investment-highlights/</loc>
		<lastmod>2012-01-26T17:48:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/investors/</loc>
		<lastmod>2012-01-17T20:00:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/corporate/profile/</loc>
		<lastmod>2012-01-16T22:40:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/12/allon-shareholders-approve-balance-of-october-prospectus-financing/</loc>
		<lastmod>2011-12-07T22:15:24+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/11/allons-intellectual-property-portfolio-strengthened-with-additional-u-s-patent/</loc>
		<lastmod>2011-11-29T23:02:11+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/11/allon-invited-to-present-at-two-major-conferences/</loc>
		<lastmod>2011-11-26T00:19:54+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/investors/shareholder-reports/</loc>
		<lastmod>2011-11-17T19:52:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/investors/special-meeting-december-7-2011/</loc>
		<lastmod>2011-11-10T22:54:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/11/allon-therapeutics-releases-q3-operating-results-and-provides-corporate-update/</loc>
		<lastmod>2011-11-08T21:52:02+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/10/allons-ceo-presenting-at-bio-investor-forum/</loc>
		<lastmod>2011-10-25T16:16:48+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/10/allon-therapeutics-announces-completion-of-patient-enrollment-in-pivotal-trial/</loc>
		<lastmod>2011-10-19T20:37:19+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/10/allon-therapeutics-completes-equity-offering/</loc>
		<lastmod>2011-10-18T16:07:04+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/09/allon-granted-important-u-s-patent-for-preclinical-compound-al-408/</loc>
		<lastmod>2011-10-14T16:34:34+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/09/allon-therapeutics-announces-overnight-marketed-equity-offering/</loc>
		<lastmod>2011-10-06T20:17:11+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/09/allon-therapeutics-amends-terms-of-offering-and-prices-offering/</loc>
		<lastmod>2011-10-06T20:00:47+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/09/allons-ceo-presenting-at-rodman-and-renshaw-global-conference-2/</loc>
		<lastmod>2011-09-13T15:57:27+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/08/allon-therapeutics-provides-pivotal-study-update-and-q2-operating-results/</loc>
		<lastmod>2011-08-12T20:48:44+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/corporate/leadership/</loc>
		<lastmod>2011-08-04T18:06:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/08/allon-granted-u-s-patent-for-davunetide-as-a-treatment-for-schizophrenia/</loc>
		<lastmod>2011-08-03T20:18:28+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/research/market/</loc>
		<lastmod>2011-07-25T21:55:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/07/new-human-imaging-data-support-the-neuroprotective-effects-of-allons-davunetide/</loc>
		<lastmod>2011-07-18T22:38:18+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/06/allon-therapeutics-releases-first-quarter-2011-operating-results/</loc>
		<lastmod>2011-07-11T17:53:55+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/allon-video/</loc>
		<lastmod>2011-07-11T16:52:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/07/allon-appoints-biotech-leader-to-its-board-of-directors/</loc>
		<lastmod>2011-07-07T00:02:58+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/investors/news-releases/</loc>
		<lastmod>2011-07-06T23:16:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/corporate/news/</loc>
		<lastmod>2011-07-06T23:15:09+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/07/b-c-life-sciences-companies-take-top-three-national-awards-at-biotech-convention/</loc>
		<lastmod>2011-07-06T21:17:11+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/contact/</loc>
		<lastmod>2011-06-15T19:20:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/06/allon-as-a-top-3-stock-pick-on-the-market-call-show-on-bnn/</loc>
		<lastmod>2011-06-14T23:56:46+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/06/allon-therapeutics-wins-national-biotech-award/</loc>
		<lastmod>2011-06-06T16:16:15+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/05/allon-updates-progress-of-pivotal-phase-23-clinical-trial/</loc>
		<lastmod>2011-05-18T20:25:26+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/05/practical-neurology-in-the-pipeline/</loc>
		<lastmod>2011-05-13T23:51:29+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/corporate/news/in-the-news/</loc>
		<lastmod>2011-05-13T16:19:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/investors/allon-2011-agm-materials/</loc>
		<lastmod>2011-05-11T18:43:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/01/allon-receives-fda-approval-to-begin-phase-i-human-clinical-trials/</loc>
		<lastmod>2011-04-26T19:27:16+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/01/allon-begins-phase-i-human-clinical-trials-for-lead-product-al-108/</loc>
		<lastmod>2011-04-26T19:25:52+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/01/allon-therapeutics-scientist-presents-preclinical-data-to-u-s-neurologists/</loc>
		<lastmod>2011-04-26T19:24:24+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/06/allon-therapeutics-product-al-108-successful-in-phase-ia-clinical-trial/</loc>
		<lastmod>2011-04-26T19:19:45+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/06/allon-therapeutics-to-present-science-and-clinical-updates-at-washington-and-philadelphia-conferences/</loc>
		<lastmod>2011-04-26T19:19:32+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/06/allon-files-ind-to-begin-clinical-trials-for-second-product-al-208/</loc>
		<lastmod>2011-04-26T19:17:57+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/06/allon-animal-study-confirms-blood-brain-barrier-penetration-of-lead-product-candidates-al-108-and-al-208/</loc>
		<lastmod>2011-04-26T19:16:41+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/06/allon-begins-enrolment-for-al-208-phase-ii-clinical-trial/</loc>
		<lastmod>2011-04-26T19:11:22+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/08/allon-begins-dosing-for-al-108-phase-ib-clinical-trial/</loc>
		<lastmod>2011-04-26T19:08:50+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/05/allon-therapeutics-releases-first-quarter-operating-results-5/</loc>
		<lastmod>2011-04-26T18:58:33+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/06/allon-therapeutics-forms-steering-committee-for-phase-ii-human-trial/</loc>
		<lastmod>2011-04-26T18:55:57+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/03/allon-shows-statistically-significant-improvement-in-schizophrenia-imaging-study/</loc>
		<lastmod>2011-04-26T18:49:23+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/temp/</loc>
		<lastmod>2011-04-26T18:27:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2004/12/allon-granted-european-patent-for-learning-and-memory-compound/</loc>
		<lastmod>2011-04-26T18:19:57+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/11/allon-therapeutics-releases-third-quarter-operating-results/</loc>
		<lastmod>2011-04-26T18:18:39+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/11/allon-therapeutics-releases-third-quarter-operating-results-7/</loc>
		<lastmod>2011-04-26T18:14:01+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/12/allon-therapeutics-presents-at-ibcs-eurotides-conference/</loc>
		<lastmod>2011-04-26T18:10:51+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/02/allon-files-ind-for-approval-of-schizophrenia-phase-ii-clinical-trials/</loc>
		<lastmod>2011-04-26T18:03:21+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/08/allon-named-%e2%80%9ctop-10%e2%80%9d-partnering-candidate-by-expert-conference/</loc>
		<lastmod>2011-04-26T17:55:01+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/09/allons-ceo-presenting-at-rodman-and-renshaw-global-conference/</loc>
		<lastmod>2011-04-26T17:35:03+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/11/allons-founding-scientist-illana-gozes-awarded-olson-prize-from-peptides-journal/</loc>
		<lastmod>2011-04-26T17:31:42+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/11/allon-receives-michael-j-fox-foundation-grant-for-parkinsons-disease-research/</loc>
		<lastmod>2011-04-26T17:22:37+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/02/allon-announces-davunetide-improves-motor-function-and-brain-pathology-in-a-parkinsons-disease-model/</loc>
		<lastmod>2011-04-26T17:19:24+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/02/allon-ceo-to-present-at-bio-ceo-investor-conference/</loc>
		<lastmod>2011-04-26T17:13:48+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/patient-resources/</loc>
		<lastmod>2011-04-21T20:05:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/03/allon-announces-presentation-of-davunetide-data-during-10th-international-conference-on-alzheimers-and-parkinsons-disease-2/</loc>
		<lastmod>2011-04-11T18:23:35+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/03/the-new-economy-award-interview-with-ceo-gordon-mccauley-videothe-new-economy-award-interview-with-ceo-gordon-mccauley-video/</loc>
		<lastmod>2011-04-11T17:15:07+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/healthcare-professionals/</loc>
		<lastmod>2011-04-11T16:33:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/07/study-pre-dementia-is-rising-especially-in-men/</loc>
		<lastmod>2011-04-06T16:43:05+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/04/allon-presents-at-bio-europe-partnering-meeting/</loc>
		<lastmod>2011-04-06T16:38:08+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/03/allon%e2%80%99s-ceo-presenting-at-life-science-innovation-northwest/</loc>
		<lastmod>2011-04-06T16:34:15+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/05/allon-therapeutics-announces-publication-of-davunetide-data-demonstrating-cognition-improvement-in-schizophrenia-model/</loc>
		<lastmod>2011-04-06T16:32:58+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/10/allon%e2%80%99s-ceo-presenting-at-bio-investor-forum/</loc>
		<lastmod>2011-04-06T16:22:17+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/01/ceo-to-present-at-biotech-showcase-2011/</loc>
		<lastmod>2011-04-06T16:19:42+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/04/xconomy-allon-treads-into-the-great-unknown-alzheimer%e2%80%99s-disease-with-new-kind-of-drug/</loc>
		<lastmod>2011-04-06T16:16:19+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/08/allon-appoints-professor-trevor-robbins-to-scientific-advisory-board/</loc>
		<lastmod>2011-04-05T23:24:28+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/07/a-looming-pre-dementia-crisis-bnn-speaks-to-gordon-mccauley/</loc>
		<lastmod>2011-04-05T23:23:32+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/07/abc-news-breakthrough-in-alzheimers-research/</loc>
		<lastmod>2011-04-05T23:20:41+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/09/allon-granted-australian-patent-for-learning-and-memory-compound/</loc>
		<lastmod>2011-04-05T22:58:24+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/07/medscape-medical-news-experimental-agent-improves-memory-in-mci/</loc>
		<lastmod>2011-04-05T22:55:42+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/10/allon-to-present-new-data-at-two-international-neuroscience-meetings/</loc>
		<lastmod>2011-04-05T22:47:27+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/10/allon-therapeutics-launches-8-million-financing/</loc>
		<lastmod>2011-04-05T22:47:21+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/03/allon-ceo-to-present-at-life-science-innovation-northwest-and-live-0nline-at-retailinvestorconferences-com/</loc>
		<lastmod>2011-04-05T22:46:06+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/01/fda-and-allon-agree-on-special-protocol-assessment-for-pivotal-trial-in-progressive-supranuclear-palsy/</loc>
		<lastmod>2011-04-05T22:40:03+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/02/allon-granted-key-japanese-patent-for-davunetide/</loc>
		<lastmod>2011-04-05T22:32:40+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/03/allon-reports-2010-audited-operating-results-and-updates-2011-plans/</loc>
		<lastmod>2011-04-05T22:27:37+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/01/allon-enrolling-patients-in-pivotal-davunetide-phase-23-trial/</loc>
		<lastmod>2011-04-05T22:22:06+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/01/allon-announces-intention-to-draw-down-200000-from-seda/</loc>
		<lastmod>2011-04-05T22:20:33+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/02/allon-appoints-dr-michael-gold-chief-medical-officer/</loc>
		<lastmod>2011-04-05T22:07:20+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2011/03/allon-presents-data-in-human-pharmacokinetic-model-at-clinical-pharmacology-conference/</loc>
		<lastmod>2011-04-05T21:43:37+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/11/allon-therapeutics-releases-third-quarter-operating-results-6/</loc>
		<lastmod>2011-04-05T21:35:04+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/research/science/</loc>
		<lastmod>2011-03-31T16:05:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/research/science/how-it-works/</loc>
		<lastmod>2011-03-30T23:45:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/research/research-publications/</loc>
		<lastmod>2011-03-30T23:34:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/corporate/careers/</loc>
		<lastmod>2011-03-30T23:33:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/research/indications/</loc>
		<lastmod>2011-03-30T23:08:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/documents/</loc>
		<lastmod>2011-03-30T21:49:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/02/allon-therapeutics-rises-40-after-postitive-drug-trial-results/</loc>
		<lastmod>2011-03-30T20:32:02+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/02/globe-mail-stocks-that-should-be-on-your-radar-screen/</loc>
		<lastmod>2011-03-30T20:31:55+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/07/los-angeles-times-how-to-converse-with-someone-who-has-alzheimers/</loc>
		<lastmod>2011-03-30T20:30:32+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/01/the-vancouver-sun-local-firms-alzheimers-drug-stirs-up-excitement/</loc>
		<lastmod>2011-03-30T20:29:02+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/02/the-vancouver-sun-allon-stock-boosted-by-test-results/</loc>
		<lastmod>2011-03-30T18:56:33+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/07/allon-drug-boosts-memory-in-pre-alzheimers-patients/</loc>
		<lastmod>2011-03-30T18:55:57+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/08/american-medical-news-alzheimers-drug-trials-surge-suggesting-new-pathways-for-care/</loc>
		<lastmod>2011-03-30T18:55:51+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/09/neuroinvestment-company-spotlight-allon-therapeutics/</loc>
		<lastmod>2011-03-30T18:54:09+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/04/business-in-vancouver-allon-therapeutics-lead-drug-to-be-fast-tracked-in-u-s/</loc>
		<lastmod>2011-03-30T18:53:47+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/08/the-new-economy-magazine-a-leading-strategy-in-a-very-big-place/</loc>
		<lastmod>2011-03-30T18:52:46+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/corporate/</loc>
		<lastmod>2011-03-29T23:30:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/video/new-economy-award-interview-video/</loc>
		<lastmod>2011-03-29T22:54:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/video/</loc>
		<lastmod>2011-03-29T22:53:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/product-development/</loc>
		<lastmod>2011-03-23T22:05:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/research/</loc>
		<lastmod>2011-03-23T22:05:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/product-development/development-status/</loc>
		<lastmod>2011-03-18T21:30:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/investors/analyst-coverage/</loc>
		<lastmod>2011-03-17T19:05:09+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/legal/</loc>
		<lastmod>2011-03-16T18:03:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/product-development/partnering/</loc>
		<lastmod>2011-03-14T22:28:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/product-development/preclinical/</loc>
		<lastmod>2011-03-14T22:24:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/03/allon-reports-2009-audited-operating-results-and-updates-2010-plans/</loc>
		<lastmod>2011-03-14T20:51:29+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/03/allon%e2%80%99s-ceo-presenting-at-bio-europe-spring/</loc>
		<lastmod>2011-03-14T20:48:32+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/03/allon%e2%80%99s-phase-1-trial-broadens-davunetide%e2%80%99s-intranasal-safety-and-dose-range/</loc>
		<lastmod>2011-03-14T20:44:30+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/03/allon-receives-european-orphan-drug-status-for-davunetide/</loc>
		<lastmod>2011-03-14T20:42:19+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/04/allon-therapeutics-announces-davunetide-receives-fda-fast-track-status-for-treatment-of-progressive-supranuclear-palsy/</loc>
		<lastmod>2011-03-14T20:41:24+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/05/allon-therapeutics-releases-first-quarter-operating-results-4/</loc>
		<lastmod>2011-03-14T20:39:21+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/08/allon-therapeutics-releases-second-quarter-operating-results-4/</loc>
		<lastmod>2011-03-14T20:35:39+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/11/allon-completes-u-s-10-million-financing-agreement-with-nordic-biotech-entity/</loc>
		<lastmod>2011-03-14T20:34:48+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/04/founding-meeting-for-ftd-study-group-led-by-allon-therapeutics-and-chaired-by-dr-adam-boxer-of-ucsf-memory-and-aging-center/</loc>
		<lastmod>2011-03-14T20:34:00+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/10/pilot-clinical-trial-meets-primary-endpoint-with-allon%e2%80%99s-davunetide/</loc>
		<lastmod>2011-03-14T17:13:44+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/11/allon-receives-qualifying-therapeutic-discovery-project-grants-for-drug-development-from-u-s-government/</loc>
		<lastmod>2011-03-14T17:13:18+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2004/10/allon-therapeutics-inc-to-present-at-biocontact-quebec-symposium/</loc>
		<lastmod>2011-03-12T00:51:27+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2004/10/allon-therapeutics-inc-to-present-at-biopartnering-europe/</loc>
		<lastmod>2011-03-12T00:51:21+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2004/11/allon-completes-pre-clinical-studies-in-preparation-for-human-trials/</loc>
		<lastmod>2011-03-12T00:51:12+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/01/allon-therapeutics-appoints-vp-clinical-operations/</loc>
		<lastmod>2011-03-12T00:51:06+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/03/allon-completes-dosing-in-phase-ia-human-clinical-trials-for-lead-product/</loc>
		<lastmod>2011-03-12T00:50:55+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/03/allon-therapeutics-compounds-show-potential-to-treat-eye-disease/</loc>
		<lastmod>2011-03-12T00:50:50+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/03/allon-cso-presents-pre-clinical-data-to-alzheimersparkinsons-conference-in-sorrento-italy/</loc>
		<lastmod>2011-03-12T00:50:44+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/04/allon-reports-2004-audited-operating-results/</loc>
		<lastmod>2011-03-12T00:50:38+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/04/allon-therapeutics-presents-at-european-biosquare-partnering-conference/</loc>
		<lastmod>2011-03-12T00:50:34+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/05/allon-reports-first-quarter-2005-operating-results/</loc>
		<lastmod>2011-03-12T00:50:01+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/08/allon-therapeutics-to-present-at-orion-securities-10th-annual-healthcare-conference/</loc>
		<lastmod>2011-03-12T00:49:58+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/04/allon-therapeutics-compounds-show-potential-to-repair-central-nervous-system-cells-after-disease-or-injury/</loc>
		<lastmod>2011-03-12T00:49:24+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/04/allon-therapeutics-to-present-at-technology-and-life-sciences-forum/</loc>
		<lastmod>2011-03-12T00:49:15+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/04/allon-therapeutics-selected-by-the-alzheimers-disease-cooperative-study/</loc>
		<lastmod>2011-03-12T00:49:09+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/04/allon-therapeutics-selected-to-present-at-beyond-science-2005-conference/</loc>
		<lastmod>2011-03-12T00:49:02+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/05/allon-therapeutics-to-present-at-biofinance-2005-conference/</loc>
		<lastmod>2011-03-12T00:48:57+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/08/allon-therapeutics-arranges-6-2-million-financing/</loc>
		<lastmod>2011-03-12T00:48:53+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/08/allon-reports-second-quarter-operating-results/</loc>
		<lastmod>2011-03-12T00:48:48+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/08/allon-begins-dosing-in-phase-i-human-trial-of-second-product-for-mild-cognitive-impairment/</loc>
		<lastmod>2011-03-12T00:48:44+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/08/journal-of-neuroscience-study-shows-potential-of-allon-therapeutics-compounds-to-protect-brain-cells/</loc>
		<lastmod>2011-03-12T00:48:38+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/08/allon-therapeutics-completes-6-3-million-financing/</loc>
		<lastmod>2011-03-12T00:48:32+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/09/allon-therapeutics-appoints-gordon-mccauley-to-board-of-directors/</loc>
		<lastmod>2011-03-12T00:48:28+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/09/allon-therapeutics-to-list-shares-on-the-toronto-stock-exchange/</loc>
		<lastmod>2011-03-12T00:48:22+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/09/allon-%e2%80%9crings-bell%e2%80%9d-to-celebrate-toronto-stock-exchange-listing/</loc>
		<lastmod>2011-03-12T00:47:39+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/02/allon-therapeutics-al-208-product-successful-in-phase-i-clinical-trial/</loc>
		<lastmod>2011-03-12T00:47:33+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/07/journal-article-confirms-mechanism-of-allons-drugs/</loc>
		<lastmod>2011-03-12T00:47:28+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/10/allon-completes-dosing-in-phase-i-human-clinical-trials-for-al-208-product/</loc>
		<lastmod>2011-03-12T00:46:54+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/11/allon-selected-as-one-of-canadas-top-10-life-sciences-for-investment-and-partnership-opportunities/</loc>
		<lastmod>2011-03-12T00:46:49+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/11/allon-selected-as-one-of-canadas-top-10-life-sciences-for-investment-and-partnership-opportunities-2/</loc>
		<lastmod>2011-03-12T00:46:43+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/11/allon-releases-new-data-confirming-its-lead-products-penetrate-blood-brain-barrier-2/</loc>
		<lastmod>2011-03-12T00:46:32+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/01/allon-therapeutics-announces-milestones-for-2006/</loc>
		<lastmod>2011-03-12T00:46:25+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/03/allon-begins-dosing-first-patient-for-al-208-phase-ib-clinical-trial/</loc>
		<lastmod>2011-03-12T00:46:17+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/03/allon-reports-2005-audited-operating-results/</loc>
		<lastmod>2011-03-12T00:46:11+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/05/allon-therapeutics-presents-csf-and-bioavailability-data-at-ibcs-tides-2006/</loc>
		<lastmod>2011-03-12T00:46:06+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/05/allon-therapeutics-releases-first-quarter-operating-results/</loc>
		<lastmod>2011-03-12T00:45:59+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/07/allons-compound-shows-effect-on-both-classic-hallmarks-of-alzheimers/</loc>
		<lastmod>2011-03-12T00:45:48+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/07/new-allon-publication-confirms-potential-in-stroke-conditions/</loc>
		<lastmod>2011-03-12T00:45:43+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/08/allon-files-cta-to-add-canadian-sites-to-phase-ii-clinical-trial/</loc>
		<lastmod>2011-03-12T00:45:37+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/08/allon-therapeutics-releases-second-quarter-operating-results/</loc>
		<lastmod>2011-03-12T00:44:45+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/11/allon-completes-dosing-for-al-108-phase-ib-clinical-trial/</loc>
		<lastmod>2011-03-12T00:43:43+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/11/allon-therapeutics-announces-final-closing-of-10-million-private-placement/</loc>
		<lastmod>2011-03-12T00:43:30+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/12/allon-receives-approval-for-phase-ii-clinical-trial-in-alzheimers-related-condition/</loc>
		<lastmod>2011-03-12T00:43:20+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/01/allon-drug-selected-for-clinical-trial-in-the-treatment-of-cognitive-impairment-in-schizophrenia/</loc>
		<lastmod>2011-03-12T00:43:12+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/01/allon-confirms-progress-in-al-208-phase-ii-clinical-trial/</loc>
		<lastmod>2011-03-12T00:42:59+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/01/michael-j-fox-foundation-funds-allon-to-evaluate-al-108-for-parkinsons-disease/</loc>
		<lastmod>2011-03-12T00:42:48+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/01/allon-therapeutics-confirms-milestones-for-2007-and-makes-further-scientific-progress/</loc>
		<lastmod>2011-03-12T00:42:39+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/02/allon-therapeutics-to-present-at-bio-ceo-investor-conference-in-new-york/</loc>
		<lastmod>2011-03-12T00:42:02+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/03/allon-product-al-108-successful-in-phase-ib-clinical-trial/</loc>
		<lastmod>2011-03-12T00:41:56+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/09/allon-commences-phase-ii-schizophrenia-trial-and-updates-clinical-progress/</loc>
		<lastmod>2011-03-12T00:40:33+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/03/allon-to-present-data-at-alzheimers-parkinsons-conference/</loc>
		<lastmod>2011-03-12T00:40:11+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/03/allon-receives-approval-to-begin-a-phase-ii-clinical-trial-for-schizophrenia/</loc>
		<lastmod>2011-03-12T00:40:04+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/03/allon-reports-2006-audited-operating-results-and-updates-2007-plans/</loc>
		<lastmod>2011-03-12T00:39:59+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/04/allon-therapeutics-to-present-new-data-at-leerink-swann-alzheimers-conference/</loc>
		<lastmod>2011-03-12T00:39:54+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/04/allon-therapeutics-confirms-oral-bioavailability-of-al-309/</loc>
		<lastmod>2011-03-12T00:39:47+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/05/allon-therapeutics-inc-enters-into-agreement-for-a-15-million-bought-deal-of-units/</loc>
		<lastmod>2011-03-12T00:39:41+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/05/allon-therapeutics-releases-first-quarter-operating-results-2/</loc>
		<lastmod>2011-03-12T00:39:34+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/05/allon-therapeutics-closes-15-0-million-bought-deal-financing/</loc>
		<lastmod>2011-03-12T00:39:28+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/06/allon-granted-us-patent-for-composition-of-matter/</loc>
		<lastmod>2011-03-12T00:39:20+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/06/allon-therapeutics-to-present-at-international-cns-disease-congress/</loc>
		<lastmod>2011-03-12T00:39:09+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/06/226/</loc>
		<lastmod>2011-03-12T00:38:59+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/08/allon-appoints-vice-president-of-business-development/</loc>
		<lastmod>2011-03-12T00:38:26+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/10/allon-therapeutics-completes-enrolment-for-phase-ii-alzheimer%e2%80%99s-trial/</loc>
		<lastmod>2011-03-12T00:38:20+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/10/allon-adds-additional-efficacy-evidence-and-publishes-important-review-of-alzheimers/</loc>
		<lastmod>2011-03-12T00:38:13+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/10/allon-to-participate-at-two-major-conferences/</loc>
		<lastmod>2011-03-12T00:38:07+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/11/allon-therapeutics-releases-third-quarter-operating-results-2/</loc>
		<lastmod>2011-03-12T00:38:01+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/01/preclinical-studies-show-allons-drug-al-108-impacts-alzheimers-pathology-and-behaviour/</loc>
		<lastmod>2011-03-12T00:37:21+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/06/allon-therapeutics-human-efficacy-data-to-be-featured-at-worlds-leading-alzheimers-disease-conference/</loc>
		<lastmod>2011-03-12T00:37:16+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/02/allon-to-study-al-108-drug-distribution-in-alzheimers-patients/</loc>
		<lastmod>2011-03-12T00:31:38+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/12/allon-therapeutics-completes-dosing-in-phase-ii-clinical-trial-in-alzheimer%e2%80%99s-program/</loc>
		<lastmod>2011-03-12T00:10:52+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/01/allon-therapeutics-confirms-milestones-for-2008/</loc>
		<lastmod>2011-03-12T00:10:45+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/01/allon-trial-studies-pharmacokinetics-of-al-108-al-208/</loc>
		<lastmod>2011-03-12T00:10:38+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/02/allons-phase-ii-clinical-trial-shows-statistically-significant-efficacy-on-human-cognition-and-memory/</loc>
		<lastmod>2011-03-12T00:10:22+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/05/allon-data-demonstrate-potential-of-al-309-as-a-new-neuropathy-treatment/</loc>
		<lastmod>2011-03-12T00:10:03+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/05/allon-therapeutics-releases-first-quarter-operating-results-3/</loc>
		<lastmod>2011-03-12T00:09:57+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/05/allon-reports-2007-audited-operating-results-and-updates-2008-plans/</loc>
		<lastmod>2011-03-12T00:09:50+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/05/allon-appoints-chief-medical-officer-for-expanding-clinical-program/</loc>
		<lastmod>2011-03-12T00:09:42+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/05/allon-therapeutics-reviews-clinical-development-program-at-rodman-and-renshaw-healthcare-conference/</loc>
		<lastmod>2011-03-12T00:09:33+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/05/allon-completes-dosing-in-phase-ii-cognitive-impairment-trial/</loc>
		<lastmod>2011-03-12T00:09:19+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/06/allon-therapeutics-enters-into-agreement-for-a-20-million-bought-deal-of-commonshares/</loc>
		<lastmod>2011-03-12T00:08:39+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/07/allon-granted-u-s-patent-for-lead-product-in-new-technology-platform/</loc>
		<lastmod>2011-03-12T00:07:39+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/07/allon-therapeutics-completes-20-million-bought-deal-offering-of-common-shares/</loc>
		<lastmod>2011-03-12T00:07:35+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/07/allon-therapeutics-presents-al-108-human-efficacy-data-at-world%e2%80%99s-leading-alzheimer%e2%80%99s-disease-conference/</loc>
		<lastmod>2011-03-12T00:07:28+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/07/allon-therapeutics-al-108-human-efficacy-data-presented-to-two-icad-2008-scientific-workshops/</loc>
		<lastmod>2011-03-12T00:07:10+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/08/allon-therapeutics-releases-second-quarter-operating-results-3/</loc>
		<lastmod>2011-03-12T00:07:02+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/08/pharmacokinetics-study-confirms-therapeutic-enabling-quantities-of-allon%e2%80%99s-drugs-al-108-and-al-208-in-human-cerebrospinal-fluid/</loc>
		<lastmod>2011-03-12T00:06:52+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/08/allon-therapeutics-releases-phase-ii-mci-cabg-results-3/</loc>
		<lastmod>2011-03-12T00:06:20+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/08/allon-therapeutics-releases-phase-ii-mci-cabg-results-2/</loc>
		<lastmod>2011-03-12T00:06:04+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/08/allon-therapeutics-releases-phase-ii-mci-cabg-results/</loc>
		<lastmod>2011-03-12T00:05:48+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/10/allon-granted-u-s-patent-for-new-class-of-drug-candidates-2/</loc>
		<lastmod>2011-03-12T00:05:28+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/10/allon-granted-u-s-patent-for-new-class-of-drug-candidates/</loc>
		<lastmod>2011-03-12T00:05:06+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/12/allon%e2%80%99s-ceo-presenting-at-bio-ceo-conference-in-nycallon%e2%80%99s-founder-honoured-for-neuroscience-research/</loc>
		<lastmod>2011-03-12T00:04:45+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/11/allon-therapeutics-releases-third-quarter-operating-results-5/</loc>
		<lastmod>2011-03-12T00:04:14+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/11/allon-therapeutics-reviews-product-development-at-bio-europe-2008/</loc>
		<lastmod>2011-03-12T00:03:54+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/11/allon-drugs-receive-u-s-patent-for-treatment-of-neuropathy/</loc>
		<lastmod>2011-03-12T00:03:06+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2008/12/patient-enrolment-completed-in-phase-ii-clinical-trial-evaluating-allon%e2%80%99s-al-108-in-schizophrenia-related-cognitive-impairmen/</loc>
		<lastmod>2011-03-12T00:02:52+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/01/allon-therapeutics-announces-milestones-for-2009/</loc>
		<lastmod>2011-03-12T00:00:58+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/02/allon-therapeutics-wins-2009-best-small-cap-ir-award/</loc>
		<lastmod>2011-03-12T00:00:44+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/02/allons-ceo-presenting-at-bio-ceo-conference-in-nyc/</loc>
		<lastmod>2011-03-12T00:00:27+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/03/allon-reports-2008-audited-operating-results-and-updates-2009-plans/</loc>
		<lastmod>2011-03-12T00:00:12+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/03/allon-presents-data-at-alzheimer%e2%80%99sparkinson%e2%80%99s-conference-in-prague/</loc>
		<lastmod>2011-03-12T00:00:00+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/03/allon-ceo-to-present-at-cowen-and-company-investment-conference/</loc>
		<lastmod>2011-03-11T23:59:15+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/04/issued-u-s-patent-strengthens-ip-for-allon-technology-platform/</loc>
		<lastmod>2011-03-11T23:59:01+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/05/allon-receives-notice-of-allowance-from-european-patent-office-for-lead-compound-davunetide-nap-as-alzheimer%e2%80%99s-treatment/</loc>
		<lastmod>2011-03-11T23:58:47+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/06/allon-releases-results-of-phase-ii-schizophrenia-cognitive-impairment-clinical-trial/</loc>
		<lastmod>2011-03-11T23:58:34+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/07/allon-ceo-to-present-at-noble-financial-investment-conference/</loc>
		<lastmod>2011-03-11T23:58:18+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/08/allon-therapeutics-releases-second-quarter-operating-results-5/</loc>
		<lastmod>2011-03-11T23:57:31+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/08/allon-ceo-to-present-at-canaccord-adams-global-growth-conference/</loc>
		<lastmod>2011-03-11T23:56:58+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/09/allon-ceo-to-present-at-rodman-and-renshaw-annual-global-investment-conference/</loc>
		<lastmod>2011-03-11T23:56:38+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/10/canadian-patent-strengthens-ip-for-allon%e2%80%99s-2nd-technology-platform-2/</loc>
		<lastmod>2011-03-11T23:56:25+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/10/canadian-patent-strengthens-ip-for-allon%e2%80%99s-2nd-technology-platform/</loc>
		<lastmod>2011-03-11T23:55:57+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/11/allon-therapeutics-releases-third-quarter-operating-results-4/</loc>
		<lastmod>2011-03-11T23:55:36+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/11/allon-chosen-as-%e2%80%9ctop-10-partnering-candidate%e2%80%9d-and-presenting-at-major-partnership-conference/</loc>
		<lastmod>2011-03-11T23:50:52+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2009/12/phase-iia-clinical-data-confirms-potential-of-allon%e2%80%99s-davunetide-as-a-treatment-for-cognitive-impairment-in-schizophrenia-patients/</loc>
		<lastmod>2011-03-11T23:50:34+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/01/299/</loc>
		<lastmod>2011-03-11T23:50:19+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/01/allon%e2%80%99s-ceo-presenting-at-rodman-and-renshaw-global-conference/</loc>
		<lastmod>2011-03-11T23:49:58+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/01/fda-grants-orphan-drug-status-to-allon%e2%80%99s-davunetide-for-brain-disease/</loc>
		<lastmod>2011-03-11T23:49:38+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/01/allon-ceo-to-present-at-biotech-showcase-2010/</loc>
		<lastmod>2011-03-11T23:49:16+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/01/pilot-clinical-trial-initiated-to-evaluate-davunetide-in-tau-pathology-dementias/</loc>
		<lastmod>2011-03-11T23:48:57+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/01/allon-initiates-trial-to-expand-safety-profile-for-dementia-drug-davunetide/</loc>
		<lastmod>2011-03-11T23:48:41+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/02/allon-therapeutics-presenting-at-bio-ceo-conference/</loc>
		<lastmod>2011-03-11T23:48:23+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/02/allon-presents-peripheral-neuropathy-preclinical-efficacy-data-for-al-309/</loc>
		<lastmod>2011-03-11T23:48:04+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/03/allon-enters-into-10-million-standby-equity-distribution-agreement/</loc>
		<lastmod>2011-03-11T23:47:40+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/03/allon-adopts-shareholder-rights-plan/</loc>
		<lastmod>2011-03-11T23:46:56+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/05/allon%e2%80%99s-ceo-presenting-at-rodman-renshaw-global-conference/</loc>
		<lastmod>2011-03-11T23:43:40+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/06/allon%e2%80%99s-ceo-presenting-at-needham-annual-healthcare-conference/</loc>
		<lastmod>2011-03-11T23:43:31+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/07/allon-to-address-pharma-executives-at-euro-biotech-forum-2/</loc>
		<lastmod>2011-03-11T23:41:46+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2010/08/allon%e2%80%99s-ceo-presenting-at-canaccord-genuity-growth-conference/</loc>
		<lastmod>2011-03-11T23:39:07+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/03/allon-completes-patient-dosing-for-al-208-phase-ib-clinical-trial/</loc>
		<lastmod>2011-03-11T23:31:30+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/02/allon-therapeutics-appoints-dr-martin-barkin-to-board-of-directors/</loc>
		<lastmod>2011-03-11T23:31:10+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/12/new-allon-publication-shows-key-role-of-adnp-in-embryo-development/</loc>
		<lastmod>2011-03-11T23:31:00+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/08/allon-therapeutics-releases-second-quarter-operating-results-2/</loc>
		<lastmod>2011-03-11T23:30:49+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2007/08/allon-and-turns-expand-collaboration-for-phase-ii-schizophrenia-trial/</loc>
		<lastmod>2011-03-11T23:30:39+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/09/canadian-patient-recruitment-begins-for-allons-al-208-phase-ii-clinical-trial/</loc>
		<lastmod>2011-03-11T23:30:24+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2006/05/scientific-paper-confirms-mechanism-of-allons-drugs/</loc>
		<lastmod>2011-03-11T23:29:44+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/06/allon-director-resigns-to-accept-new-position/</loc>
		<lastmod>2011-03-11T23:28:19+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2005/07/phase-1-human-clinical-trials-start-next-month/</loc>
		<lastmod>2011-03-11T23:24:21+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/2004/12/allon-files-ind-for-approval-of-alzheimers-clinical-trials/</loc>
		<lastmod>2011-03-11T23:21:34+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/investors/stock-quote/</loc>
		<lastmod>2010-12-11T00:21:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://www.allontherapeutics.com/investors/information-request/</loc>
		<lastmod>2010-12-10T01:49:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.6</priority>
	</url>
</urlset>
